Inquiry Basket
CAS No.:
Cat No.: BADC-01422
4.5 
DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA) is a click-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs).
Structure of
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA) is a complex molecule used in targeted drug delivery and cancer therapy. Here are some key applications of DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA):
Antibody-Drug Conjugates (ADCs): This compound is utilized in the design of ADCs, which are engineered to target and destroy cancer cells specifically. The DBCO group enables site-specific conjugation to antibodies, ensuring precise delivery of the cytotoxic payload. By selectively targeting cancer cells, ADCs minimize off-target effects and improve the therapeutic index.
Cellular Imaging: DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA) can be used in cellular imaging applications to study cell surface proteins and internalization mechanisms. The DBCO moiety reacts with azide-modified biomolecules in a bioorthogonal fashion, allowing for the visualization of molecular interactions. This helps researchers to track the localization and fate of the compound within living cells.
Drug Delivery Systems: This molecule is fundamental in developing advanced drug delivery systems such as polymeric nanoparticles and liposomes. The PEG4 spacer improves solubility and biocompatibility, while the cleavable VC-PAB linker ensures the controlled release of the active drug within the target cells. This enhances the efficacy and safety profile of nanoparticle-based therapeutics.
Cancer Therapeutics Research: DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA) is widely used in preclinical research to explore new cancer therapeutic strategies. By studying the pharmacodynamics and pharmacokinetics of this compound, researchers can optimize its design for better targeting and reduced toxicity. This accelerates the development of next-generation cancer therapies.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-00811 | Duocarmycin DM free base | 1116745-06-2 | |
| BADC-00337 | Seco-Duocarmycin TM | 1142188-60-0 | |
| BADC-00223 | Duocarmycin A | 118292-34-5 | |
| BADC-00362 | Duocarmycin B1 | 124325-93-5 | |
| BADC-00341 | Seco-Duocarmycin SA | 152785-82-5 | |
| BADC-00605 | Duocarmycin TM | 157922-77-5 | |
| BADC-00332 | Seco-DuocarmycinCN | 1613286-54-6 | |
| BADC-00333 | Seco-DuocarmycinDMG | 1613286-55-7 | |
| BADC-00342 | Seco-Duocarmycin MA | 1613286-57-9 | |
| BADC-00609 | Duocarmycin MB | 1613286-58-0 |
What is DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA)?
DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA) is an advanced ADC linker-payload construct incorporating a cleavable VC-PAB linker, PEG4 spacer, DBCO reactive handle, and the DNA-alkylating Seco-Duocarmycin SA derivative.
12/3/2017
We would like to know how DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA) releases its payload.
The VC-PAB linker is cleaved enzymatically after ADC internalization, releasing DMEA-Seco-Duocarmycin SA. The PEG4 spacer enhances solubility, while the DBCO moiety facilitates efficient bioorthogonal conjugation to antibodies.
18/12/2018
Could you kindly inform us what stability properties this conjugate offers?
DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA) is designed for high plasma stability to prevent premature payload release. The PEG4 linker and DBCO handle ensure chemical stability during storage and conjugation processes.
23/9/2020
Good morning! Could you kindly advise which antibodies are compatible with DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA)?
This conjugate is suitable for site-specific conjugation to azide-functionalized antibodies via DBCO-azide click chemistry. This enables precise ADC construction with controlled drug-to-antibody ratios.
9/6/2021
Dear team, what are the typical applications of this product in research?
DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA) is primarily used in preclinical and clinical ADC research, particularly for targeted oncology therapies requiring potent DNA-alkylating payloads with selective delivery.
5/1/2016
— Dr. Caroline Lewis, ADC Lead Scientist (UK)
DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA) was a key component in our ADC program, demonstrating high conjugation efficiency.
23/9/2020
— Mr. Victor Nguyen, Research Chemist (USA)
Excellent quality DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA) with consistent batch purity, enabling reproducible results.
5/1/2016
— Dr. Isabelle Martin, Medicinal Chemist (France)
The linker performed superbly in our site-specific conjugation workflow, with minimal by-products and high yield.
9/6/2021
— Prof. Lars Andersen, Biochemistry Professor (Denmark)
BOC Sciences delivered DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA) on time and with excellent documentation.
12/3/2017
— Dr. Emilia Rossi, Conjugation Specialist (Italy)
The solubility and stability profile of DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA) matched our project requirements perfectly.
— Mr. Thomas Lee, Senior Scientist (USA)
Highly reactive and pure DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA). Enabled smooth ADC assembly in multiple trials.
18/12/2018
DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA)
Required fields are marked with *
DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA)
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
